Sanofi: Positive phase III data in IPT

(CercleFinance.com) - At the ASH annual meeting in San Diego (7-10 December), Sanofi unveils positive phase III results for its rilzabrutinib in the treatment of adults with persistent or chronic immune thrombocytopenia (ITP).


This pivotal LUNA 3 study showed a rapid and durable platelet response, a reduction in bleeding, use of emergency treatment and physical fatigue, as well as an improvement in patients' quality of life scores.

These results illustrate the safety and efficacy profile of this first BTK inhibitor, and its potential interest in the treatment of IPT. Rilzabrutinib is currently under review by regulatory authorities in the US and the European Union.


Copyright (c) 2024 CercleFinance.com. All rights reserved.